Daiichinkyo CoFRA:D4S +1.32%76 PB Ratio is 2.86 as of Jul. 06, 2026, which is 24% below its 10-year median of 3.77. GuruFocus rates FRA:D4S with a GF Score™ of 76/100 and a GF Value™ of €32.73 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 921 Drug Manufacturers companies, Daiichinkyo Co ranks worse than 66.34% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-07-06), Daiichinkyo Co's share price is €14.246. Daiichinkyo Co's Book Value per Share for the quarter that ended in Mar. 2026 was €4.99. Hence, Daiichinkyo Co's PB Ratio of today is 2.86.
Good Sign:
Daiichi Sankyo Co Ltd stock PB Ratio (=2.9) is close to 5-year low of 2.7.
The historical rank and industry rank for Daiichinkyo Co's PB Ratio or its related term are showing as below:
FRA:D4S'
s PB Ratio Range Over the Past 10 Years
Min: 1.3 Med: 3.77 Max: 6.62
Current: 2.9
During the past 13 years, Daiichinkyo Co's highest PB Ratio was 6.62. The lowest was 1.30. And the median was 3.77.
FRA:D4S's PB Ratio is ranked worse than 66.34% of 921
companies
in the Drug Manufacturers industry
Industry Median: 1.93
vs FRA:D4S: 2.90
During the past 12 months, Daiichinkyo Co's average Book Value Per Share Growth Rate was 5.20% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 6.60% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 7.10% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 4.90% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Daiichinkyo Co was 16.80% per year. The lowest was -10.90% per year. And the median was 4.05% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Daiichinkyo Co PB Ratio Related Terms
Daiichinkyo Co PB Ratio Historical Data
* Premium members only.
The historical data trend for Daiichinkyo Co's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - General subindustry, Daiichinkyo Co's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Daiichinkyo Co PB Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Daiichinkyo Co's PB Ratio distribution charts can be found below:
* The bar in red indicates where Daiichinkyo Co's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
Daiichinkyo Co's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Daiichinkyo Co (FRA:D4S) has a PB Ratio of 2.86 as of Jul. 06, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Daiichinkyo Co and its competitors. This is 24% below median its historical median of 3.77. Over the past decade, Daiichinkyo Co's PB Ratio has ranged from 1.30 to 6.62. According to the industry distribution chart, Daiichinkyo Co ranks #611 out of 921 companies in the Drug Manufacturers industry, placing it in the top 66.3%.
Is Daiichinkyo Co's PB Ratio too high?
Daiichinkyo Co's current PB Ratio of 2.86 is 24% below median its 10-year median of 3.77. Over the past 10 years, this metric has ranged from a low of 1.30 to a high of 6.62. The Drug Manufacturers industry median PB Ratio is 1.93. Daiichinkyo Co's value of 2.86 is 48.2% above this industry median. Based on the distribution chart, Daiichinkyo Co ranks #611 out of 921 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Daiichinkyo Co has a GF Score™ of 76/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Daiichinkyo Co's PB Ratio compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Daiichinkyo Co ranks #611 out of 921 companies for PB Ratio. This places Daiichinkyo Co in the lower half of its industry. The industry median PB Ratio is 1.93. Daiichinkyo Co's value of 2.86 is 48.2% above this benchmark. Historically, Daiichinkyo Co's own PB Ratio has ranged from 1.30 to 6.62 over the past decade. While the company's 10-year median is 3.77 vs. the industry median of 1.93, Daiichinkyo Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Drug Manufacturers company?
The median PB Ratio among Drug Manufacturers companies is 1.93, based on 921 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Daiichinkyo Co's current PB Ratio of 2.86 is 48.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Daiichinkyo Co and its competitors. For the Drug Manufacturers industry, the median PB Ratio is 1.93 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Daiichinkyo Co's current PB Ratio is 2.86, which is 24% below median its own 10-year median of 3.77. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Daiichinkyo Co stock overvalued right now?
Based on GuruFocus' analysis, Daiichinkyo Co (FRA:D4S) is currently considered Significantly Undervalued. The stock's GF Value™ is €32.73, compared to a current price of €14.25 — trading 56.5% below its estimated fair value. The current PB Ratio is 2.86, which is 24% below median its 10-year median of 3.77 and 48.2% above the Drug Manufacturers industry median of 1.93. Daiichinkyo Co's overall GF Score™ is 76/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Daiichinkyo Co (FRA:D4S), the current PB Ratio is 2.86 as of Jul. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Daiichinkyo Co (FRA:D4S) Overvalued in 2026?
Based on GuruFocus' analysis, Daiichinkyo Co stock appears to be undervalued.
The current stock price of €14.25 is trading 56.5% below its estimated GF Value™ of €32.73.
GuruFocus considers Daiichinkyo Co to be Significantly Undervalued.
Key valuation signals for FRA:D4S:
PB Ratio: 2.86 (24% below median its 10-year median of 3.77)
GF Value™: €32.73 vs. price of €14.25 (56.5% below fair value)
Industry Position: 48.2% above the Drug Manufacturers median (#611 of 921)
No single metric tells the full story. See the FRA:D4S stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Daiichi Sankyo was established by the merger of Daiichi Pharmaceuticals and Sankyo in 2005. As of 2024, approximately one quarter of revenue comes from its Japan businesses, which will shrink in the future as the company expands its global footprint. Its primary growth driver is its leading platform of antibody drug conjugates, or ADCs. Its lead ADCs are Enhertu (HER2), Datroway (TROP2), I-DXd (B7-H3), HER3-DXd (HER3), and R-DXd (CDH6). Enhertu was first approved in the US in December 2019, and Datroway was first approved in January 2025.
76GF Score
Get the complete analysis for FRA:D4S
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:D4S has been successfully added to your 
